Spyre Therapeutics, Inc. — Director's Dealing 2017

Mar 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-03-20

Reporting Person: York Charles N II (Chief Financial Officer and VP)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-20	Employee Stock Option (right to buy)	$8.03	A	90000	Acquired	2027-03-19	Common Stock (90000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.